Abstract

Bordetella pertussis strains, which have lost the ability to produce antigens, such as pertactin – Prn, pertussis toxin – Ptx, filamentous haemagglutinin – FHA, fimbriae type 2 and 3 – Fim 2 and 3, tracheal colonization factor – TcfA, have recently been isolated in countries with a high vaccination coverage. The emergence of such isolates might have resulted from B. pertussis natural evolution course or adaptive mechanisms, allowing increased circulation of the pathogen in vaccinated populations. So far, the majority of described mutants were deficient in the Prn production. Prn deficient isolates were found in countries which use acellular pertussis vaccines (aP) in routine immunization programmes. The increase of frequency of Prn¯ strains isolation was correlated with the period of routine vaccination with aP vaccines. In most countries, the spread of these isolates has resulted from independent mutations rather than from the expansion of a single clone. Prn¯ isolates were collected from patients showing typical clinical symptoms of pertussis found for Prn+ strains. Results of in vitro and in vivo studies have shown that Prn¯, Ptx¯ and FHA¯ isolates retain cytotoxic properties, and besides Ptx¯ isolates, were lethal in intranasally infected mice. Further explanation of the impact of antigen deficiencies on virulence and transmission of B. pertussis in the context of the continuous increase of pertussis incidence is necessary to develop a new, optimized strategy of pertussis prevention.

References

• 1. Abramson T., Kedem H., Relman D.A.: Proinflammatory and proapoptoticactivities associated with Bordetella pertussis filamentoushemagglutinin. Infect. Immun., 2001; 69: 2650-2658
  Google Scholar
• 2. Advani A., Hallander H.O., Dalby T., Krogfelt K.A., Guiso N., NjamkepoE., von Könnig C.H., Riffelmann M., Mooi F.R., Sandven P., LutynskaA., Fry N.K., Mertsola J., He Q.: Pulsed-field gel electrophoresisanalysis of Bordetella pertussis isolates circulating in Europe from 1998to 2009. J. Clin. Microbiol., 2013; 51: 422-428
  Google Scholar
• 3. Bamberger E., Abu Raya B., Cohen L., Golan-Shany O., DavidsonS., Geffen Y., Srugo I.: Pertussis resurgence associated with pertactin-deficientand genetically divergent Bordetella pertussis isolates inIsrael. Pediatr. Infect. Dis. J., 2015; 34: 898-900
  Google Scholar
• 4. Barkoff A.M., Mertsola J., Guillot S., Guiso N., Berbers G., He Q.:Appearance of Bordetella pertussis strains not expressing the vaccineantigen pertactin in Finland. Clin. Vaccine Immunol., 2012; 19:1703-1704
  Google Scholar
• 5. Bodilis H., Guiso N.: Virulence of pertactin-negative Bordetellapertussis isolates from infants, France. Emerg. Infect. Dis., 2013; 19:471-474
  Google Scholar
• 6. Bogdanowicz J.: Krztusiec. Państwowy Zakład Wydawnictw Lekarskich,Warszawa 1954
  Google Scholar
• 7. Bouchez V., Brun D., Cantinelli T., Dore G., Njamkepo E., Guiso N.:First report and detailed characterization of B. pertussis isolates notexpressing pertussis toxin or pertactin. Vaccine, 2009; 27: 6034-6041
  Google Scholar
• 8. Bouchez V., Brun D., Dore G., Njamkepo E., Guiso N.: Bordetellaparapertussis isolates not expressing pertactin circulating in France.Clin. Microbiol. Infect., 2011; 17: 675-682
  Google Scholar
• 9. Bouchez V., Caro V., Levillain E., Guigon G., Guiso N.: Genomiccontent of Bordetella pertussis clinical isolates circulating in areas ofintensive children vaccination. PLoS One, 2008; 3: e2437
  Google Scholar
• 10. Bouchez V., Hegerle N., Strati F., Njamkepo E., Guiso N.: Newdata on vaccine antigen deficient Bordetella pertussis isolates. Vaccines,2015; 3: 751-770
  Google Scholar
• 11. Bowden K.E., Williams M.M., Cassiday P.K., Milton A., PawloskiL., Harrison M., Martin S.W., Meyer S., Qin X., DeBolt C., Tasslimi A.,Syed N., Sorrell R., Tran M., Hiatt B., Tondella M.L.: Molecular epidemiologyof the pertussis epidemic in Washington State in 2012. J.Clin. Microbiol., 2014; 52: 3549-3557
  Google Scholar
• 12. Bradford P.G., Rubin R.P.: Pertussis toxin inhibits chemotacticfactor-induced phospholipase C stimulation and lysosomal enzymesecretion in rabbit neutrophils. FEBS Lett., 1985; 183: 317-320
  Google Scholar
• 13. Brandt S.J., Dougherty R.W., Lapetina E.G., Niedel J.E.: Pertussistoxin inhibits chemotactic peptide-stimulated generation of inositolphosphates and lysosomal enzyme secretion in human leukemic(HL-60) cells. Proc. Natl. Acad. Sci. USA, 1985; 82: 3277-3280
  Google Scholar
• 14. Cahill E.S., O’Hagan D.T., Illum L., Redhead K.: Mice are protectedagainst Bordetella pertussis infection by intra-nasal immunizationwith filamentous haemagglutinin. FEMS Microbiol. Lett.,1993; 107: 211-216
  Google Scholar
• 15. Carbonetti N.H.: Immunomodulation in the pathogenesis ofBordetella pertussis infection and disease. Curr. Opin. Pharmacol.,2007; 7: 272-278
  Google Scholar
• 16. Carbonetti N.H., Artamonova G.V., Andreasen C., Dudley E., MaysR.M., Worthington Z.E.: Suppression of serum antibody responsesby pertussis toxin after respiratory tract colonization by Bordetellapertussis and identification of an immunodominant lipoprotein. Infect.Immun., 2004; 72: 3350-3358
  Google Scholar
• 17. Centers for Disease Control and Prevention (CDC): Pertussisepidemic-Washington, 2012. MMWR Morb. Mortal. Wkly. Rep., 2012;61: 517-522
  Google Scholar
• 18. Cherry J.D.: Pertussis: challenges today and for the future. PLoSPathog., 2013; 9: e1003418
  Google Scholar
• 19. Cherry J.D., Gornbein J., Heininger U., Stehr K.: A search for serologiccorrelates of immunity to Bordetella pertussis cough illnesses.Vaccine, 1998; 16: 1901-1906
  Google Scholar
• 20. Chiappini E., Stival A., Galli L., de Martino M.: Pertussis re-emergencein the post-vaccination era. BMC Infect. Dis., 2013; 13: 151
  Google Scholar
• 21. Clarke M., McIntyre P.B., Blyth C.C., Wood N., Octavia S., SintchenkoV., Giles L., Quinn H., Hill V., Hanly G., Lan R., Marshall H.S.: Therelationship between Bordetella pertussis genotype and clinical severityin Australian children with pertussis. J. Infect., 2016; 72: 171-178
  Google Scholar
• 22. de Gouw D., Diavatopoulos D.A., Bootsma H.J., Hermans P.W.,Mooi F.R.: Pertussis: a matter of immune modulation. FEMS Microbiol.Rev., 2011; 35: 441-474
  Google Scholar
• 23. Diavatopoulos D.A., Cummings C.A., Schouls L.M., Brinig M.M.,Relman D.A., Mooi F.R.: Bordetella pertussis, the causative agent ofwhooping cough, evolved from a distinct, human-associated lineageof B. bronchiseptica. PLoS Pathog., 2005; 1: e45
  Google Scholar
• 24. Dubé E., Vivion M., MacDonald N.E.: Vaccine hesitancy, vaccinerefusal and the anti-vaccine movement: influence, impact and implications.Expert Rev. Vaccines, 2015; 14: 99-117
  Google Scholar
• 25. Fedele G., Bianco M., Ausiello C.M.: The virulence factors ofBordetella pertussis: talented modulators of host immune response.Arch. Immunol. Ther. Exp., 2013; 61: 445-457
  Google Scholar
• 26. Finn T.M., Stevens L.A.: Tracheal colonization factor: a Bordetellapertussis secreted virulence determinant. Mol. Microbiol., 1995;16: 625-634
  Google Scholar
• 27. Geuijen C.A., Willems R.J., Bongaerts M., Top J., Gielen H., MooiF.R.: Role of the Bordetella pertussis minor fimbrial subunit, FimD, incolonization of the mouse respiratory tract. Infect. Immun., 1997;65: 4222-4228
  Google Scholar
• 28. Geuijen C.A., Willems R.J., Mooi F.R.: The major fimbrial subunitof Bordetella pertussis binds to sulfated sugars. Infect. Immun.,1996; 64: 2657-2665
  Google Scholar
• 29. Gogol E.B., Cummings C.A., Burns R.C., Relman D.A.: Phase variationand microevolution at homopolymeric tracts in Bordetellapertussis. BMC Genomics, 2007; 8: 122
  Google Scholar
• 30. Gustafsson L., Hallander H.O., Olin P., Reizenstein E., StorsaeterJ.: A controlled trial of a two-component acellular, a five-componentacellular, and a whole-cell pertussis vaccine. N. Engl. J. Med.,1996; 334: 349-355
  Google Scholar
• 31. Gzyl A., Augustynowicz E., Gniadek G., Rabczenko D., Dulny G.,Slusarczyk J.: Sequence variation in pertussis S1 subunit toxin andpertussis genes in Bordetella pertussis strains used for the whole-cellpertussis vaccine produced in Poland since 1960: efficiency of theDTwP vaccine-induced immunity against currently circulating B.pertussis isolates. Vaccine, 2004; 22: 2122-2128
  Google Scholar
• 32. He Q., Mertsola J.: Factors contributing to pertussis resurgence.Future Microbiol., 2008; 3: 329-339
  Google Scholar
• 33. He Q., Viljanen M.K., Olander R.M., Bogaerts H., De Grave D.,Ruuskanen O, Mertsola J.: Antibodies to filamentous hemagglutininof Bordetella pertussis and protection against whooping coughin schoolchildren. J. Infect. Dis., 1994; 170: 705-708
  Google Scholar
• 34. Hegerle N., Dore G., Guiso N.: Pertactin deficient Bordetella pertussispresent a better fitness in mice immunized with an acellularpertussis vaccine. Vaccine, 2014; 32: 6597-6600
  Google Scholar
• 35. Hegerle N., Guiso N.: Antibody-mediated inhibition of Bordetellapertussis adenylate cyclase-haemolysin-induced macrophagecytotoxicity is influenced by variations in the bacterial population.Microbiology, 2014; 160: 962-969
  Google Scholar
• 36. Hegerle N., Guiso N.: Bordetella pertussis and pertactin-deficientclinical isolates: lessons for pertussis vaccines. Expert Rev. Vaccines,2014; 13: 1135-1146
  Google Scholar
• 37. Hegerle N., Paris A.S., Brun D., Dore G., Njamkepo E., Guillot S.,Guiso N.: Evolution of French Bordetella pertussis and Bordetella parapertussisisolates: increase of Bordetellae not expressing pertactin.Clin. Microbiol. Infect., 2012; 18: E340-E346
  Google Scholar
• 38. Heikkinen E., Kallonen T., Saarinen L., Sara R., King A.J., MooiF.R., Soini J.T., Mertsola J., He Q.: Comparative genomics of Bordetellapertussis reveals progressive gene loss in Finnish strains. PLoSOne, 2007; 2: e904
  Google Scholar
• 39. Hellwig S.M., Rodriguez M.E., Berbers G.A., van de Winkel J.G.,Mooi F.R.: Crucial role of antibodies to pertactin in Bordetella pertussisimmunity. J. Infect. Dis., 2003; 188: 738-742
  Google Scholar
• 40. Inatsuka C.S., Xu Q., Vujkovic-Cvijin I., Wong S., Stibitz S., MillerJ.F., Cotter P.A.: Pertactin is required for Bordetella species to resistneutrophil-mediated clearance. Infect. Immun., 2010; 78: 2901-2909
  Google Scholar
• 41. Ishibashi Y., Relman D.A., Nishikawa A.: Invasion of human respiratoryepithelial cells by Bordetella pertussis: possible role for a filamentoushemagglutinin Arg-Gly-Asp sequence and α5β1 integrin.Microb. Pathog., 2001; 30: 279-288
  Google Scholar
• 42. Jakinovich A., Sood S.K.: Pertussis: still a cause of death, sevendecades into vaccination. Curr. Opin. Pediatr., 2014; 26: 597-604
  Google Scholar
• 43. Kallonen T., Gröndahl-Yli-Hannuksela K., Elomaa A., LutyńskaA., Fry N.K., Mertsola J., He Q.: Differences in the genomic contentof Bordetella pertussis isolates before and after introduction of pertussisvaccines in four European countries. Infect. Genet. Evol., 2011;11: 2034-2042
  Google Scholar
• 44. King A.J., Berbers G., van Oirschot H.F., Hoogerhout P., KnippingK., Mooi F.R.: Role of the polymorphic region 1 of the Bordetella pertussisprotein pertactin in immunity. Microbiology, 2001; 147: 2885-2895
  Google Scholar
• 45. King A.J., van Gorkom T., van der Heide H.G., Advani A., vander Lee S.: Changes in the genomic content of circulating Bordetellapertussis strains isolated from the Netherlands, Sweden, Japan andAustralia: adaptive evolution or drift? BMC Genomics, 2010; 11: 64
  Google Scholar
• 46. Komatsu E., Yamaguchi F., Abe A., Weiss A.A., Watanabe M.: Synergiceffect of genotype changes in pertussis toxin and pertactinon adaptation to an acellular pertussis vaccine in the murine intranasalchallenge model. Clin. Vaccine. Immunol., 2010; 17: 807-812
  Google Scholar
• 47. Kurova N., Njamkepo E., Brun D., Tseneva G., Guiso N.: Monitoringof Bordetella isolates circulating in Saint Petersburg, Russiabetween 2001 and 2009. Res. Microbiol., 2010; 161: 810-815
  Google Scholar
• 48. Lam C., Octavia S., Ricafort L., Sintchenko V., Gilbert G.L., WoodN., McIntyre P., Marshall H., Guiso N., Keil A.D., Lawrence A., RobsonJ., Hogg G., Lan R.: Rapid Increase in pertactin-deficient Bordetellapertussis isolates, Australia. Emerg. Infect. Dis., 2014; 20: 626-633
  Google Scholar
• 49. Leininger E., Roberts M., Kenimer J.G., Charles I.G., FairweatherN., Novotny P., Brennan M.J.: Pertactin, an Arg-Gly-Asp-containingBordetella pertussis surface protein that promotes adherence of mammaliancells. Proc. Natl. Acad. Sci. USA, 1991; 88: 345-349
  Google Scholar
• 50. Liko J., Robison S.G., Cieslak P.R.: Priming with whole-cell versusacellular pertussis vaccine. N. Engl. J. Med., 2013; 368: 581-582
  Google Scholar
• 51. Locht C.: Molecular aspects of Bordetella pertussis pathogenesis.Int. Microbiol., 1999; 2: 137-144
  Google Scholar
• 52. Locht C., Bertin P., Menozzi F.D., Renauld G.: The filamentoushaemagglutinin, a multifaceted adhesion produced by virulent Bordetellaspp. Mol. Microbiol., 1993; 9: 653-660
  Google Scholar
• 53. Martin S.W., Pawloski L., Williams M., Weening K., DeBolt C., QinX., Reynolds L., Kenyon C., Giambrone G., Kudish K., Miller L., SelvageD., Lee A., Skoff T.H., Kamiya H. i wsp.: Pertactin-negative Bordetellapertussis strains: evidence for a possible selective advantage. Clin.Infect. Dis., 2015; 60: 223-227
  Google Scholar
• 54. Mastrantonio P., Spigaglia P., van Oirschot H., van der Heide H.G.,Heuvelman K., Stefanelli P., Mooi F.R.: Antigenic variants in Bordetellapertussis strains isolated from vaccinated and unvaccinated children.Microbiology, 1999; 145: 2069-2075
  Google Scholar
• 55. Mattoo S., Cherry J.D.: Molecular pathogenesis, epidemiology,and clinical manifestations of respiratory infections due to Bordetellapertussis and other Bordetella subspecies. Clin. Microbiol Rev.,2005; 18: 326-382
  Google Scholar
• 56. McCarthy M.: Vaccine refusal may have contributed to California’s 2010 pertussis outbreak, study finds. Br. Med. J., 2013; 347: f6109
  Google Scholar
• 57. Medical Research Council 1956: VACCINATION against whooping-cough;relation between protection in children and resultsof laboratory tests; a report to the Whooping-cough ImmunizationCommittee of the Medical Research Council and to the medical officersof health for Cardiff, Leeds, Leyton, Manchester, Middlesex,Oxford, Poole, Tottenham, Walthamstow, and Wembley. Br. Med. J.,1956; 2: 454-462
  Google Scholar
• 58. Melvin J.A., Scheller E.V., Miller J.F., Cotter P.A.: Bordetella pertussispathogenesis: current and future challenges. Nat Rev Microbiol.,2014; 12: 274-288
  Google Scholar
• 59. Mills K.H., Ryan M., Ryan E., Mahon B.P.: A murine model inwhich protection correlates with pertussis vaccine efficacy in childrenreveals complementary roles for humoral and cell-mediatedimmunity in protection against Bordetella pertussis. Infect. Immun.,1998; 66: 594-602
  Google Scholar
• 60. Miyaji Y., Otsuka N., Toyoizumi-Ajisaka H., Shibayama K., KamachiK.: Genetic analysis of Bordetella pertussis isolates from the2008-2010 pertussis epidemic in Japan. PLoS One, 2013; 8: e77165
  Google Scholar
• 61. Mooi F.R.: Bordetella pertussis and vaccination: the persistenceof a genetically monomorphic pathogen. Infect. Genet. Evol., 2010;10: 36-49
  Google Scholar
• 62. Mooi F.R., van Loo I.H., van Gent M., He Q., Bart M.J., HeuvelmanK.J., de Greeff S.C., Diavatopoulos D., Teunis P., Nagelkerke N.,Mertsola J.: Bordetella pertussis strains with increased toxin productionassociated with pertussis resurgence. Emerg. Infect. Dis., 2009;15: 1206-1213
  Google Scholar
• 63. Mooi F.R., van der Maas N.A., de Melker H.E.: Pertussis resurgence:waning immunity and pathogen adaptation – two sides of thesame coin. Epidemiol. Infect., 2014; 142: 685-694
  Google Scholar
• 64. Mosiej E., Augustynowicz E., Zawadka M., Dabrowski W., Lutyń-ska A.: Strain variation among Bordetella pertussis isolates circulatingin Poland after 50 years of whole-cell pertussis vaccine use. J. Clin.Microbiol., 2011; 49: 1452-1457
  Google Scholar
• 65. Mosiej E., Zawadka M., Krysztopa-Grzybowska K., Polak M., AugustynowiczE., Piekarska K., Lutyńska A.: Sequence variation in virulence-relatedgenes of Bordetella pertussis isolates from Poland in theperiod 1959-2013. Eur. J. Clin. Microbiol. Infect. Dis., 2015; 34: 147-152
  Google Scholar
• 66. Njamkepo E., Cantinelli T., Guigon G., Guiso N.: Genomic analysisand comparison of Bordetella pertussis isolates circulating in low andhigh vaccine coverage areas. Microbes. Infect., 2008; 10: 1582-1586
  Google Scholar
• 67. Olin P., Rasmussen F., Gustafsson L., Hallander H.O., Heijbel H.:Randomised controlled trial of two-component, three-component,and five-component acellular pertussis vaccines compared withwhole-cell pertussis vaccine. Ad Hoc Group for the Study of PertussisVaccines. Lancet, 1997; 350: 1569-1577
  Google Scholar
• 68. Otsuka N., Han H.J., Toyoizumi-Ajisaka H., Nakamura Y., ArakawaY., Shibayama K., Kamachi K.: Prevalence and genetic characterizationof pertactin-deficient Bordetella pertussis in Japan. PLoSOne, 2012; 7: e31985
  Google Scholar
• 69. Packard E.R., Parton R., Coote J.G., Fry N.K.: Sequence variationand conservation in virulence-related genes of Bordetella pertussisisolates from the UK. J. Med. Microbiol., 2004; 53: 355-365
  Google Scholar
• 70. Parkhill J., Sebaihia M., Preston A., Murphy L.D., Thomson N., Harris D.E., Holden M.T., Churcher C.M., Bentley S.D., Mungall K.L.,Cerdeño-Tárraga A.M., Temple L., James K., Harris B., Quail M.A.i wsp.: Comparative analysis of the genome sequences of Bordetellapertussis, Bordetella parapertussis and Bordetella bronchiseptica. Nat.Genet., 2003; 35: 32-40
  Google Scholar
• 71. Pawloski L.C., Queenan A.M., Cassiday P.K., Lynch A.S., HarrisonM.J., Shang W., Williams M.M., Bowden K.E., Burgos-Rivera B., Qin X.,Messonnier N., Tondella M.L.: Prevalence and molecular characterizationof pertactin-deficient Bordetella pertussis in the United States.Clin. Vaccine Immunol., 2014; 21: 119-125
  Google Scholar
• 72. Queenan A.M., Cassiday P.K., Evangelista A.: Pertactin-negativevariants of Bordetella pertussis in the United States. N. Engl. J. Med.,2013; 368: 583-584
  Google Scholar
• 73. Quinlan T., Musser K.A., Currenti S.A., Zansky S.M., Halse T.A.:Pertactin-negative variants of Bordetella pertussis in New York State:A retrospective analysis, 2004-2013. Mol. Cell. Probes, 2014; 28:138-140
  Google Scholar
• 74. Rodríguez M.E., Hellwig S.M., Pérez Vidakovics M.L., BerbersG.A., van de Winkel J.G.: Bordetella pertussis attachment to respiratoryepithelial cells can be impaired by fimbriae-specific antibodies.FEMS Immunol. Med. Microbiol., 2006; 46: 39-47
  Google Scholar
• 75. Safarchi A., Octavia S., Luu L.D., Tay C.Y., Sintchenko V., Wood N,Marshall H., McIntyre P., Lan R.: Pertactin negative Bordetella pertussisdemonstrates higher fitness under vaccine selection pressure ina mixed infection model. Vaccine, 2015; 33: 6277-6281
  Google Scholar
• 76. Sato H., Sato Y.: Bordetella pertussis infection in mice: correlationof specific antibodies against two antigens, pertussis toxin, and filamentoushemagglutinin with mouse protectivity in an intracerebralor aerosol challenge system. Infect. Immun., 1984; 46: 415-421
  Google Scholar
• 77. Sato H., Sato Y.: Relationship between structure and biologicaland protective activities of pertussis toxin. Dev. Biol. Stand., 1991;73: 121-132
  Google Scholar
• 78. Scheller E.V., Cotter P.A.: Bordetella filamentous hemagglutininand fimbriae: critical adhesins with unrealized vaccine potential.Pathog. Dis., 2015; 73: ftv079
  Google Scholar
• 79. Sealey K.L., Harris S.R., Fry N.K., Hurst L.D., Gorringe A.R., ParkhillJ., Preston A.: Genomic analysis of isolates from the United Kingdom 2012 pertussis outbreak reveals that vaccine antigen genes areunusually fast evolving. J. Infect. Dis., 2015; 212: 294-301
  Google Scholar
• 80. Serra D.O., Conover M.S., Arnal L., Sloan G.P., Rodriguez M.E.,Yantorno O.M., Deora R.: FHA-mediated cell-substrate and cell-celladhesions are critical for Bordetella pertussis biofilm formation onabiotic surfaces and in the mouse nose and the trachea. PLoS One,2011; 6: e28811
  Google Scholar
• 81. Shahin R.D., Amsbaugh D.F., Leef M.F.: Mucosal immunizationwith filamentous hemagglutinin protects against Bordetella pertussisrespiratory infection. Infect. Immun., 1992; 60: 1482-1488
  Google Scholar
• 82. Sheridan S.L., Ware R.S., Grimwood K., Lambert S.B.: Numberand order of whole cell pertussis vaccines in infancy and diseaseprotection. JAMA, 2012; 308: 454-456
  Google Scholar
• 83. Shuel M., Jamieson F.B., Tang P., Brown S., Farrell D., Martin I.,Stoltz J., Tsang R.S.: Genetic analysis of Bordetella pertussis in Ontario,Canada reveals one predominant clone. Int. J. Infect. Dis., 2013;17: e413-417
  Google Scholar
• 84. Spangrude G.J., Sacchi F., Hill H.R., van Epps D.E., Daynes R.A.:Inhibition of lymphocyte and neutrophil chemotaxis by pertussistoxin. J. Immunol., 1985; 135: 4135-4143
  Google Scholar
• 85. Stefanelli P., Fazio C., Fedele G., Spensieri F., Ausiello C.M., MastrantonioP.: A natural pertactin deficient strain of Bordetella pertussisshows improved entry in human monocyte-derived dendriticcells. New Microbiol., 2009; 32: 159-166
  Google Scholar
• 86. Stefanoff P., Paradowska-Stankiewicz I.A., Lipke M., KarasekE., Rastawicki W., Zasada A., Samuels S., Czajka H., Pebody R.G.: Incidence of pertussis in patients of general practitioners in Poland.Epidemiol. Infect., 2014; 142: 714-723
  Google Scholar
• 87. Storsaeter J., Hallander H.O., Gustafsson L., Olin P.: Levels of anti–pertussis antibodies related to protection after household exposureto Bordetella pertussis. Vaccine, 1998; 16: 1907-1916
  Google Scholar
• 88. Theofiles A.G., Cunningham S.A., Chia N., Jeraldo P.R., Quest D.J.,Mandrekar J.N., Patel R.: Pertussis outbreak, Southeastern Minnesota, 2012 Mayo Clin. Proc., 2014; 89: 1378-1388
  Google Scholar
• 89. Thierry-Carstensen B., Dalby T., Stevner M.A., Robbins J.B.,Schneerson R., Trollfors B.: Experience with monocomponent acellularpertussis combination vaccines for infants, children, adolescentsand adults – a review of safety, immunogenicity, efficacy andeffectiveness studies and 15 years of field experience. Vaccine, 2013;31: 5178-5191
  Google Scholar
• 90. Tsang R.S., Shuel M., Jamieson F.B., Drews S., Hoang L., HorsmanG., Lefebvre B., Desai S., St-Laurent M.: Pertactin-negative Bordetellapertussis strains in Canada: characterization of a dozen isolates basedon a survey of 224 samples collected in different parts of the countryover the last 20 years. Int. J. Infect. Dis., 2014; 28: 65-69
  Google Scholar
• 91. van Gent M., Heuvelman C.J., van der Heide H.G., Hallander H.O.,Advani A., Guiso N., Wirsing von Kőnig C.H., Vestrheim D.F., DalbyT., Fry N.K., Pierard D., Detemmerman L., Zavadilova J., FabianovaK., Logan C. i wsp.: Analysis of Bordetella pertussis clinical isolatescirculating in European countries during the period 1998-2012. Eur.J. Clin. Microbiol. Infect. Dis., 2015; 34: 821-830
  Google Scholar
• 92. van Gent M., Pierard D., Lauwers S., van der Heide H.G., KingA.J., Mooi F.R.: Characterization of Bordetella pertussis clinical isolatesthat do not express the tracheal colonization factor. FEMS Immunol.Med. Microbiol., 2007; 51: 149-154
  Google Scholar
• 93. van Gent M., van Loo I.H., Heuvelman K.J., de Neeling A.J., TeunisP., Mooi F.R.: Studies on Prn variation in the mouse model andcomparison with epidemiological data. PLoS One, 2011; 6: e18014
  Google Scholar
• 94. van Hoek A.J., Campbell H., Amirthalingam G., Andrews N., MillerE.: The number of deaths among infants under one year of age inEngland with pertussis: results of a capture/recapture analysis forthe period 2001 to 2011. Euro Surveill., 2013; 18: 20414
  Google Scholar
• 95. van Loo I.H., Heuvelman K.J., King A.J., Mooi F.R.: Multilocussequence typing of Bordetella pertussis based on surface proteingenes. J. Clin. Microbiol., 2002; 40: 1994-2001
  Google Scholar
• 96. Vandebriel R.J., Hellwig S.M., Vermeulen J.P., Hoekman J.H.,Dormans J.A., Roholl P.J., Mooi F.R.: Association of Bordetella pertussiswith host immune cells in the mouse lung. Microb. Pathog.,2003; 35: 19-29
  Google Scholar
• 97. Williams M.M., Sen K., Weigand M.R., Skoff T.H., CunninghamV.A., Halse T.A., Tondella M.L., CDC Pertussis Working Group: Bordetellapertussis strain lacking pertactin and pertussis toxin. Emerg.Infect. Dis., 2016; 22: 319-322
  Google Scholar
• 98. World Health Organization: WHO – Immunization, Vaccines andBiologicals, Pertussis. http://www.who.int/immunization/topics/pertussis/en/(12.12.2015)
  Google Scholar
• 99. Zeddeman A., van Gent M., Heuvelman C.J., van der Heide H.G.,Bart M.J., Advani A., Hallander H.O., Wirsing von Konig C.H., RiffelmanM., Storsaeter J., Vestrheim D.F., Dalby T., Krogfelt K.A., Fry N.K.,Barkoff A.M. i wsp.: Investigations into the emergence of pertactin–deficient Bordetella pertussis isolates in six European countries, 1996to 2012. Euro Surveill., 2014; 19: 20881
  Google Scholar
• 100. Zhu Y.Z., Cai C.S., Zhang W., Guo H.X., Zhang J.P., Ji Y.Y., Ma G.Y.,Wu J.L., Li Q.T., Lu C.P., Guo X.K.: Immunoproteomic analysis of humanserological antibody responses to vaccination with whole-cellpertussis vaccine (WCV). PLoS One, 2010; 5: e13915
  Google Scholar

Full text